SARS-CoV-2
REPLACE COVID Trial: Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Can Be Safely Continued in Patients Admitted to Hospital With COVID-19
A recent trial by Dr. Jordana B Cohen, published in The LANCET, indicated that consistent with international society recommendations, patients admitted to the hospital with COVID-19 can safely continue treatment with renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB)) unless there is a distinct medical contraindication to ongoing therapy.
In a Recent Large Cohort Renin–Angiotensin–Aldosterone System Inhibitors Were Not Associated with Increased Risk of COVID-19 and Severe Illness
Medications acting on the renin-angiotensin-aldosterone system (RAAS), such as ACE inhibitors and angiotensin receptor blockers, did not increase the likelihood of a positive test for Covid-19 or the severity of the Covid-19. A cohort study of more than 12,500 patients conducted in a large health network in New York City, led by Dr. Reynolds, revealed. The findings of the study were recently published in the New England Journal of Medicine. Continue reading
